Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. Issue 6 (1st November 2016)

• Record Type: Journal Article
• Authors: Hirata, Shintaro; Li, Wanying; Kubo, Satoshi; Fukuyo, Shunsuke; Mizuno, Yasushi; Hanami, Kentaro; Sawamukai, Norifumi; Yamaoka, Kunihiro; Saito, Kazuyoshi; Defranoux, Nadine A.; Tanaka, Yoshiya
• Is Part Of: Modern rheumatology. Volume 26:Issue 6(2016)
• Page Start: 850
• Page End: 856
• Publication Date: 2016-11-01
• Subjects: Biomarkers -- MBDA score -- Radiographic progression -- Rheumatoid arthritis -- TNF inhibitor; Rheumatology -- Periodicals; 616.723005
• DOI: 10.3109/14397595.2016.1153449
• Languages: English
• ISSNs: 1439-7595

Abstract

Abstract: Objective : Evaluate the association between the multi-biomarker disease activity (MBDA) score and radiographic progression in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF)-α inhibitors. Methods : Change (Δ) in modified total Sharp score (mTSS) over 52 weeks and disease activity scores were examined retrospectively by Spearman's rank correlation coefficient in patients ( N = 83) with RA initiating TNF-inhibitor treatment. Relative risk (RR) of ΔmTSS >0.5 for low MBDA score and 28-joint count disease activity score (DAS28) categories and associations between ΔmTSS and MBDA score categories conditional on DAS28 categories were assessed. Results : At 52 weeks, 34% of patients had ΔmTSS >0.5 and 12% had ΔmTSS >3. Strongest correlations were observed between ΔmTSS and MBDA score ( r = 0.47) or DAS28 ( r = 0.42) at Week 24 and for area under the curve at Week 52 (MBDA score: r = 0.44, DAS28: r = 0.41), all p < 0.001. At Week 24, RR of ΔmTSS >0.5 for moderate/high MBDA score (≥30) or DAS28 (>3.2) were 6.6 ( p < 0.001) and 2.7 ( p = 0.005), respectively. Low DAS28 had greater risk of ΔmTSS >0.5 at 52 weeks when MBDA score was ≥30 ( p < 0.05). Conclusion : Higher MBDA score or DAS28 at Week 24 was associated with greater radiographic progression over 52 weeks of TNF-inhibitor treatment. MBDA score improved risk discrimination for radiographic progression within DAS28 categories.